Real-world cost-effectiveness of pharmacogenetic screening for epilepsy treatment

Neurology

Volumn 86, Issue 12, 2016, Pages 1086-1094

  Chen, Zhibin ^a,b   Liew, Danny ^a,b   Kwan, Patrick ^a,b,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; HLA B15 ANTIGEN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; HLA-B*15:02 ANTIGEN;

ADOLESCENT; ADULT; AGED; ANTICONVULSANT THERAPY; ARTICLE; CHILD; COST EFFECTIVENESS ANALYSIS; DECISION TREE; EPILEPSY; FEMALE; GENETIC SCREENING; GENOTYPING TECHNIQUE; HEALTH CARE COST; HEALTH CARE POLICY; HONG KONG; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PHARMACOGENETICS; POINT OF CARE TESTING; PRESCRIPTION; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; QUALITY ADJUSTED LIFE YEAR; RETROSPECTIVE STUDY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; VERY ELDERLY; COST BENEFIT ANALYSIS; ECONOMICS; GENETICS; MIDDLE AGED; PRESCHOOL CHILD; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; EPILEPSY; FEMALE; GENETIC TESTING; HLA-B15 ANTIGEN; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PHARMACOGENETICS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84961588707     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002484     Document Type: Article

References (38)

1. Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013; 54: 551-563.
2. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology. 1997; 49: 542-546.
3. Franciotta D, Kwan P, Perucca E. Genetic basis for idiosyncratic reactions to antiepileptic drugs. Curr Opin Neurol. 2009; 22: 144-149.
4. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004; 428: 486.
5. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics. 2006; 16: 297-306.
6. Man CB, Kwan P, Baum L, et al. Association between HLA-B 1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007; 48: 1015-1018.
7. Chang CC, Too CL, Murad S, Hussein SH. Association of HLA-B1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. Int J Dermatol. 2011; 50: 221-224.
8. US Food and Drug Administration. Information for healthcare professionals: dangerous or even fatal skin reactions-carbamazepine (marketed as Carbatrol, Equetro, Tegretol, and generics) [online]. Available at: http://www.fda. gov/Drugs/DrugSafety/Postmarketdrugsafetyinformationfor PatientsandProviders/ucm124718.htm. Accessed November 26, 2014.
9. Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B1502 screening in Taiwan. N Engl J Med. 2011; 364: 1126-1133.
10. Dong D, Sung C, Finkelstein EA. Cost-effectiveness of HLA-B1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology. 2012; 79: 1259-1267.
11. Association of the British Pharmaceutical Industry. The vision for real world data-harnessing the opportunities in the UK [online]. Available at: http://www.abpi.org. uk/our-work/library/industry/Pages/Vision-for-Real-World-Data.aspx. Accessed November 26, 2014.
12. Chen Z, Liew D, Kwan P. Effects of a HLA-B15: 02 screening policy on antiepileptic drug use and severe skin reactions. Neurology. 2014; 83: 2077-2084.
13. Cheung YK, Cheng SH, Chan EJ, Lo SV, Ng MH, Kwan P. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia. 2013; 54: 1307-1314.
14. Chen Z, Liew D, Kwan P. Real-world efficiency of pharmacogenetic screening for carbamazepine-induced severe cutaneous adverse reactions. PLoS One. 2014; 9: e96990.
15. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007; 369: 1000-1015.
16. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia. 1997; 38: 859-880.
17. Marson AG, Williamson PR, Clough H, Hutton JL, Chadwick DW; Epilepsy Monotherapy Trial Group. Carbamazepine versus valproate monotherapy for epilepsy: a meta-Analysis. Epilepsia. 2002; 43: 505-513.
18. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet. 1995; 345: 476-479.
19. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ; Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007; 68: 402-408.
20. Ng M, Ng H. Re: genetic testing prior to prescription of carbamazepine [online]. Available at: http://www.cuhk.edu. hk/med/paf/ups/HLA-B-1502.pdf. Accessed November 26, 2014.
21. Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2013; 380: 2129-2143.
22. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000; 342: 314-319.
23. Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol. 2011; 7: 803-813; quiz 14-15.
24. Elsherbiny OE, Salem MA, El-Sabbagh AH, Elhadidy MR, Eldeen SM. Quality of life of adult patients with severe burns. Burns. 2011; 37: 776-789.
25. Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008; 8: 165-178.
26. Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States: an analysis of costeffectiveness. N Engl J Med. 2005; 352: 586-595.
27. de Kok IM, van Rosmalen J, Dillner J, et al. Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ. 2012; 344: e670.
28. Pharoah PD, Sewell B, Fitzsimmons D, Bennett HS, Pashayan N. Cost effectiveness of the NHS breast screening programme: life table model. BMJ. 2013; 346: f2618.
29. US Food and Drug Administration. Information for healthcare professionals: phenytoin (marketed as Dilantin, Phenytek and generics) and fosphenytoin sodium (marketed as Cerebyx and generics) [online]. Available at: http://www.fda.gov/.Drugs/DrugSafety/PostmarketDrugSafetyInformationfor PatientsandProviders/ucm124788.htm. Accessed November 26, 2014.
30. Chung WH, Chang WC, Lee YS, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA. 2014; 312: 525-534.
31. Caudle KE, Rettie AE, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-b genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014; 96: 542-548.
32. Neumann PJ, Cohen JT, Weinstein MC. Updating costeffectiveness: the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014; 371: 796-797.
33. The World Health Organization. Cost-effectiveness thresholds [online]. Available at: http://www.who.int/.choice/costs/CER-thresholds/en/. Accessed December 4, 2014.
34. Leckband SG, Kelsoe JR, Dunnenberger HM, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-b genotype and carbamazepine dosing. Clin Pharmacol Ther. 2013; 94: 324-328.
35. McCormack M, Alfirevic A, Bourgeois S, et al. HLAA 3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011; 364: 1134-1143.
36. Amstutz U, Shear NH, Rieder MJ, et al. Recommendations for HLA-B15: 02 and HLA-A 31: 01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia. 2014; 55: 496-506.
37. Plumpton CO, Yip VLM, Alfirevic A, Marson AG, Pirmohamed M, Hughes DA. Cost-effectiveness of screening for HLA-A 31: 01 prior to initiation of carbamazepine in epilepsy. Epilepsia. 2015; 56: 556-563.
38. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015; 372: 793-795.